

# Impax Laboratories Inc (IPXL) - Financial and Strategic SWOT Analysis Review

https://marketpublishers.com/r/I72C503057EEN.html

Date: May 2017

Pages: 54

Price: US\$ 125.00 (Single User License)

ID: I72C503057EEN

## **Abstracts**

Impax Laboratories Inc (IPXL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.



Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities – A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

#### **Highlights**

Impax Laboratories Inc (Impax) is a pharmaceutical company develops, manufacture and market generic and branded pharmaceuticals by applying its formulation expertise and drug delivery technology. The company operates develops and markets proprietary branded products for CNS disorders and manufactures and markets generic pharmaceutical products representing dosage variations of several pharmaceutical compounds. The company develops marketing partnerships to leverage its technology platform and to offer alternative dosage form technologies, such as nasal sprays, injectable, patches and others. It distributes its generic pharmaceutical products through wholesalers, large retail drug chains, unrelated third-party pharmaceutical entities and others. The company has manufacturing facilities in Hayward, California; Middlesex, New Jersey; and Taiwan. Impax is headquartered in Hayward, California, the US.

Impax Laboratories Inc Key Recent Developments

Mar 27,2017: Impax Board of Directors Appoints Paul M. Bisaro President and CEO



Mar 01,2017: Impax Reports Fourth Quarter and Full Year 2016 Financial Results

Dec 20,2016: Impax Laboratories Announces Leadership Transition

Nov 28,2016: Impax Laboratories appoints new board member Nov 09,2016: Impax Reports Third Quarter 2016 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.



Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company



## **Contents**

#### **SECTION 1 - ABOUT THE COMPANY**

Impax Laboratories Inc - Key Facts

Impax Laboratories Inc - Key Employees

Impax Laboratories Inc - Key Employee Biographies

Impax Laboratories Inc - Major Products and Services

Impax Laboratories Inc - History

Impax Laboratories Inc - Company Statement

Impax Laboratories Inc - Locations And Subsidiaries

**Head Office** 

Other Locations & Subsidiaries

#### **SECTION 2 – COMPANY ANALYSIS**

Impax Laboratories Inc - Business Description

Impax Laboratories Inc - Corporate Strategy

Impax Laboratories Inc - SWOT Analysis

SWOT Analysis - Overview

Impax Laboratories Inc - Strengths

Impax Laboratories Inc - Weaknesses

Impax Laboratories Inc - Opportunities

Impax Laboratories Inc - Threats

Impax Laboratories Inc - Key Competitors

#### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

#### SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017



Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017

Impax Laboratories Inc, Recent Deals Summary

#### **SECTION 5 – COMPANY'S RECENT DEVELOPMENTS**

Mar 27, 2017: Impax Board of Directors Appoints Paul M. Bisaro President and CEO

Mar 01, 2017: Impax Reports Fourth Quarter and Full Year 2016 Financial Results

Dec 20, 2016: Impax Laboratories Announces Leadership Transition

Nov 28, 2016: Impax Laboratories appoints new board member

Nov 09, 2016: Impax Reports Third Quarter 2016 Financial Results

Aug 22, 2016: Richard A. Bierly Appointed to Impax Laboratories Board of Directors

Aug 09, 2016: Impax Reports Second Quarter 2016 Financial Results

Jul 21, 2016: Impax Names Douglas S. Boothe President of Generics Division

May 10, 2016: Impax Reports First Quarter 2016 Financial Results

Apr 14, 2016: Impax Announces the Retirement of Nigel Ten Fleming, Ph.D. and

Michael Markbreiter from its Board of Directors

#### **SECTION 6 – APPENDIX**

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer



## **List Of Tables**

#### LIST OF TABLES

Impax Laboratories Inc, Key Facts

Impax Laboratories Inc, Key Employees

Impax Laboratories Inc, Key Employee Biographies

Impax Laboratories Inc, Major Products and Services

Impax Laboratories Inc, History

Impax Laboratories Inc, Other Locations

Impax Laboratories Inc, Subsidiaries

Impax Laboratories Inc, Key Competitors

Impax Laboratories Inc, Ratios based on current share price

Impax Laboratories Inc, Annual Ratios

Impax Laboratories Inc, Annual Ratios (Cont.1)

Impax Laboratories Inc, Annual Ratios (Cont.2)

Impax Laboratories Inc, Interim Ratios

Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD

2017

Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD

2017

Impax Laboratories Inc, Recent Deals Summary

**Currency Codes** 

**Capital Market Ratios** 

**Equity Ratios** 

**Profitability Ratios** 

**Cost Ratios** 

**Liquidity Ratios** 

Leverage Ratios

**Efficiency Ratios** 



# **List Of Figures**

#### LIST OF FIGURES

Impax Laboratories Inc, Performance Chart (2012 - 2016)

Impax Laboratories Inc, Ratio Charts

Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017

Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

#### **COMPANIES MENTIONED**

Teva Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd
Par Pharmaceutical Holdings Inc
Mylan NV
Mapi Pharma Ltd
Lupin Pharmaceuticals Inc
Lannett Company Inc
Avanir Pharmaceuticals Inc
Allergan Plc



#### I would like to order

Product name: Impax Laboratories Inc (IPXL) - Financial and Strategic SWOT Analysis Review

Product link: <a href="https://marketpublishers.com/r/l72C503057EEN.html">https://marketpublishers.com/r/l72C503057EEN.html</a>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/I72C503057EEN.html">https://marketpublishers.com/r/I72C503057EEN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970